Zhejiang Hisun Pharmaceutical Co., Ltd.
600267.SS · SHH
Market closed11.32-0.670000 (-5.59%)
Key statistics
Previous close11.99
Open11.95
Day high11.98
Day low11.32
52-week high12.98
52-week low9.35
Market cap13.36B
Volume36.07M
Average volume26.13M
P/E ratio18.89
Forward P/E—
EPS0.60
Dividend yield+1.86%
Market context
Why it moved
Shares of 600267.SS fell sharply today amid broad selling pressure in the Chinese healthcare sector, as investors reacted to unfavorable regulatory or policy developments weighing on market sentiment.
What is happening
Recent company-specific developments and publisher coverage.
Moomoo · April 7, 2026Haisco Pharmaceutical (600267.SH) announced its 2025 annual performance, with a net profit attributable to shareholders of 541 million yuan, representing a year-on-year decrease of 10.06%.Pharmaceutical Technology · February 21, 2020Favilavir approved as experimental coronavirus drugBloomberg.com · November 10, 2017Pfizer Sells Stake in China's Hisun, Ending Drugs Joint VenturePharmafile · February 20, 2012Pfizer closes in on $545m China generics deal Mt Newswire · June 30, 2026Zhejiang Hisun Pharmaceutical Gets Approval for Cytomegalovirus Medication Mt Newswire · May 22, 2026Hisun Pharmaceutical Clinches NMPA Drug Registration for Prostate Cancer Treatment Mt Newswire · March 27, 2026Zhejiang Hisun Pharmaceutical Subsidiary Gets Supplementary Drug Approval for Anti-Leukemia Injection Mt Newswire · March 17, 2026China Approves Hisun Subsidiary's Clinical Trial for High Cholesterol Tablets Mt Newswire · March 3, 2026Zhejiang Hisun Pharmaceutical Secures Approval for Canine Antifungal Drug Mt Newswire · January 7, 2026Zhejiang Hisun Pharmaceutical Investee Company Applies for Hong Kong Listing Mt Newswire · January 5, 2026Hisun Pharmaceutical's Shareholder to Dispose of Entire Stake; Shares Up 3% Mt Newswire · December 24, 2025Hisun Pharmaceutical Gets China Approval for Kidney Cancer Tablets